Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
milatuzumab-doxorubicin
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Milatuzumab-doxorubicin** is an investigational CD74-directed antibody-drug conjugate composed of the humanized anti-CD74 monoclonal antibody milatuzumab covalently linked to the anthracycline payload doxorubicin. Following CD74 binding and internalization by tumor cells, doxorubicin is released and intercalates DNA while inhibiting topoisomerase II, producing replication blockade and DNA damage. The agent was initially developed by Immunomedics and subsequently studied under Gilead Sciences sponsorship in relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia; its registered Phase I/II studies were terminated. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/milatuzumab-doxorubicin-antibody-drug-conjugate-immu-110))
- Other names
- hLL1-DOXhLL-1-DOXhLL 1-DOX
02
Targets
TOP2A (DNA topoisomerase II)CD74 (Major histocompatibility complex class II invariant chain)
Beyond the preview
Go deeper on milatuzumab-doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on milatuzumab-doxorubicin.